BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

577 related articles for article (PubMed ID: 29780248)

  • 1. Incidence of symptomatic venous thromboembolism in 2372 knee and hip replacement patients after discharge: data from a thromboprophylaxis registry in Montreal, Canada.
    Senay A; Trottier M; Delisle J; Banica A; Benoit B; Laflamme GY; Malo M; Nguyen H; Ranger P; Fernandes JC
    Vasc Health Risk Manag; 2018; 14():81-89. PubMed ID: 29780248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial.
    Eriksson BI; Dahl OE; Huo MH; Kurth AA; Hantel S; Hermansson K; Schnee JM; Friedman RJ;
    Thromb Haemost; 2011 Apr; 105(4):721-9. PubMed ID: 21225098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair.
    Forster R; Stewart M
    Cochrane Database Syst Rev; 2016 Mar; 3(3):CD004179. PubMed ID: 27027384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery.
    Wolowacz SE; Roskell NS; Maciver F; Beard SM; Robinson PA; Plumb JM; Dolan G; Brenkel IJ
    Clin Ther; 2009 Jan; 31(1):194-212. PubMed ID: 19243718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of postoperative venous thromboembolism in Japanese patients undergoing total hip or knee arthroplasty: two randomized, double-blind, placebo-controlled studies with three dosage regimens of enoxaparin.
    Fuji T; Ochi T; Niwa S; Fujita S
    J Orthop Sci; 2008 Sep; 13(5):442-51. PubMed ID: 18843459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low molecular weight heparin versus other anti-thrombotic agents for prevention of venous thromboembolic events after total hip or total knee replacement surgery: a systematic review and meta-analysis.
    Lu X; Lin J
    BMC Musculoskelet Disord; 2018 Sep; 19(1):322. PubMed ID: 30193575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factor Xa Inhibitors and Direct Thrombin Inhibitors Versus Low-Molecular-Weight Heparin for Thromboprophylaxis After Total Hip or Total Knee Arthroplasty: A Systematic Review and Meta-Analysis.
    Sun G; Wu J; Wang Q; Liang Q; Jia J; Cheng K; Sun G; Wang Z
    J Arthroplasty; 2019 Apr; 34(4):789-800.e6. PubMed ID: 30685261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.
    Eriksson BI; Dahl OE; Rosencher N; Kurth AA; van Dijk CN; Frostick SP; Kälebo P; Christiansen AV; Hantel S; Hettiarachchi R; Schnee J; Büller HR;
    J Thromb Haemost; 2007 Nov; 5(11):2178-85. PubMed ID: 17764540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thromboprophylaxis with dabigatran after total hip arthroplasty in Indian patients: A subanalysis of a double-blind, double-dummy, randomized RE-NOVATE II study.
    Malhotra R; Babhulkar S; Sanjib KB; Clemens A; Dadi A; Iyer R; Kamath S; Mody B; Mutha S; Reddy G; Shah V; Shah V; Shetty N; Tapasvi S; Wadhwa M
    Asian J Surg; 2017 Apr; 40(2):145-151. PubMed ID: 27143213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials.
    Friedman RJ; Dahl OE; Rosencher N; Caprini JA; Kurth AA; Francis CW; Clemens A; Hantel S; Schnee JM; Eriksson BI;
    Thromb Res; 2010 Sep; 126(3):175-82. PubMed ID: 20434759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial.
    Eriksson BI; Dahl OE; Büller HR; Hettiarachchi R; Rosencher N; Bravo ML; Ahnfelt L; Piovella F; Stangier J; Kälebo P; Reilly P;
    J Thromb Haemost; 2005 Jan; 3(1):103-11. PubMed ID: 15634273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dabigatran: new drug. Continue to use heparin, a better-known option.
    Prescrire Int; 2009 Jun; 18(101):97-9. PubMed ID: 19637411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Symptomatic in-hospital deep vein thrombosis and pulmonary embolism following hip and knee arthroplasty among patients receiving recommended prophylaxis: a systematic review.
    Januel JM; Chen G; Ruffieux C; Quan H; Douketis JD; Crowther MA; Colin C; Ghali WA; Burnand B;
    JAMA; 2012 Jan; 307(3):294-303. PubMed ID: 22253396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty.
    Levitan B; Yuan Z; Turpie AG; Friedman RJ; Homering M; Berlin JA; Berkowitz SD; Weinstein RB; DiBattiste PM
    Vasc Health Risk Manag; 2014; 10():157-67. PubMed ID: 24707185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effectiveness of new oral anticoagulants and standard thromboprophylaxis in patients having total hip or knee replacement: a systematic review.
    Adam SS; McDuffie JR; Lachiewicz PF; Ortel TL; Williams JW
    Ann Intern Med; 2013 Aug; 159(4):275-84. PubMed ID: 24026260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elective hip and knee arthroplasty and the effect of rivaroxaban and enoxaparin thromboprophylaxis on wound healing.
    Sindali K; Rose B; Soueid H; Jeer P; Saran D; Shrivastava R
    Eur J Orthop Surg Traumatol; 2013 May; 23(4):481-6. PubMed ID: 23412293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin: a multi-institutional cohort study of patients who underwent hip or knee arthroplasty. Canadian Collaborative Group.
    Leclerc JR; Gent M; Hirsh J; Geerts WH; Ginsberg JS
    Arch Intern Med; 1998 Apr; 158(8):873-8. PubMed ID: 9570173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aspirin Can Be Used as Prophylaxis for Prevention of Venous Thromboembolism After Revision Hip and Knee Arthroplasty.
    Deirmengian GK; Heller S; Smith EB; Maltenfort M; Chen AF; Parvizi J
    J Arthroplasty; 2016 Oct; 31(10):2237-40. PubMed ID: 27118182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology of venous thromboembolism after lower limb arthroplasty: the FOTO study.
    Samama CM; Ravaud P; Parent F; Barré J; Mertl P; Mismetti P
    J Thromb Haemost; 2007 Dec; 5(12):2360-7. PubMed ID: 17908282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of switch-therapy modalities (enoxaparin to rivaroxaban/dabigatran) and enoxaparin monotherapy after hip and knee replacement.
    Özler T; Uluçay Ç; Önal A; Altıntaş F
    Acta Orthop Traumatol Turc; 2015; 49(3):255-9. PubMed ID: 26200403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.